Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

151 results about "Genome engineering" patented technology

Genome engineering refers to the strategies and techniques developed in recent years for the targeted, specific modification of the genetic information – or genome – of living organisms. It represents a very active field of research because of the wide range of possible applications, particularly in the areas of human health - the correction of a gene carrying a harmful mutation, the production of therapeutic proteins, the elimination of persistent viral sequences - agricultural biotechnology - the development of new generations of genetically modified plants - and for the development of research tools - for example, to explore the function of a gene. Early technologies developed to insert a gene into a living cell, such as transgenesis, are limited by the random nature of the insertion of the new sequence into the genome. The new gene is positioned blindly, and may inactivate or disturb the functioning of other genes or even cause severe unwanted effects; it may trigger a process of cancerization, for example. Furthermore, these technologies offer no degree of reproducibility, as there is no guarantee that the new sequence will be inserted at the same place in two different cells.

Engineered CRISPR-Cas9 nucleases with altered PAM specificity

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Owner:THE GENERAL HOSPITAL CORP

Methods for improving genome engineering and regeneration in plant

This document relates to methods and materials for genome engineering in eukaryotic cells, and particularly to methods for increasing genome engineering (i.e. transformation or genome editing) efficiency via delivery of one or more booster polypeptides, and boost genes, with genome engineering components.
Owner:KWS SAAT SE & CO KGAA

Nucleic acid-guided DNA synthesis

The present disclosure provides systems, compositions, methods, and kits, for guided DNA synthesis and genome engineering. Particularly, the present disclosure provides systems, compositions, methods, and kits comprising a defense-associated reverse transcriptase (DRT), or a nucleic acid encoding thereof, and an engineered target nucleic acid comprising one or more sequence of interest, or a nucleic acid encoding thereof.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Cells having solid tumor targeting backbone and use thereof

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC

RNA-guided gene editing and gene regulation

Disclosed herein are system-related compositions based on clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) 9 and methods of using the system-related compositions based on CRISPR / Cas9 for altering gene expression and genome engineering. Also disclosed herein are compositions and methods of using the compositions for altering gene expression and genome engineering in muscles such as skeletal muscle and cardiac muscle.
Owner:DUKE UNIV

Solid tumor targeting backbone promoting effector cell differentiation and function

Provided are methods and compositions for obtaining functionally enhanced immune cells, and derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC

Compositions and methods for crispr / CAS9 based reactivation of human angelman syndrome

PCT designated stageWO2026006542A2Organic active ingredientsSpecial deliveryGenomic mutationGenetics
Systems and methods for highly-effective CRISPR-Cas based genomic editing within human chromosome 15q11-q13 have been developed as therapeutic interventions for Angelman Syndrome (AS). Selective single guide RNA molecules (sgRNAs) that impart enhanced CRISPR-Cas editing of genomic mutations associated with Angelman Syndrome in human cells are described. The engineered sgRNAs induce activity of non-pathogenic, paternal UBE3A alleles to reduce, reverse and / or prevent the causative neurodevelopmental defects of AS in a subject in need thereof. Compositions and methods of engineered crRNAs, sgRNAs thereof and ribonucleoprotein (RNP) complexes thereof are provided for enhanced genomic engineering with increased on-off target specificity and on-target editing efficacy for treatment of AS.
Owner:YALE UNIVERSITY

Engineered CRISPR-Cas9 nucleases with altered PAM specificity

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Owner:THE GENERAL HOSPITAL CORP

Efficient homologous recombination method suitable for bifidobacteria and application of efficient homologous recombination method

The invention belongs to the field of microbial genetic engineering, and particularly relates to an efficient homologous recombination method suitable for bifidobacteria and application of the efficient homologous recombination method. Specifically, the invention discloses a method for constructing and screening the combination of the single-chain annealing protein and the single-chain binding protein for the first time. According to the method, a single-chain annealing protein and a single-chain binding protein are jointly constructed in an escherichia coli-bifidobacterium shuttle expression vector, and co-expression of the single-chain annealing protein and the single-chain binding protein in bifidobacterium longum is realized, so that the homologous recombination capability of the bifidobacterium longum is remarkably improved. According to the method disclosed by the invention, the homologous recombination efficiency of genome editing of the bifidobacterium longum is greatly improved, the absolute genome editing efficiency of the bifidobacterium longum is improved to 0.00009792% from the original level which is almost undetectable, and the research and application progress of genome engineering of the strain is remarkably promoted, so that the method has a good practical application value.
Owner:SHANDONG UNIV

Systems and methods for increased production of recombinant biopolymers via genome engineering and downregulation of basal expression

Recombinant E. coli strains and synthetic protein sequence designs are leveraged for production of disordered polypeptides such as spidroins and elastin-like peptides (ELPs). These disordered polypeptides, the high-titer production of which has proven difficult, include repeating structural motifs from a small selection of amino acid residues, resulting in lack of well-defined tertiary and quaternary structure. The recombinant E. coli include expression vectors with genes encoding for the disordered polypeptide product. Expression of these genes is controlled by a promoter that downregulates and substantially inhibits basal expression in the recombinant bacteria. Further, the recombinant bacteria include mutations to one or more stress-response genes from wild-type E. coli, such as yggw, yedv, yedw, yedy, spec, speb, uspc, hcha, loip, mltc, envz, ompr, yhgf, or hupb. The recombinant E. coli enable production of high titers of disordered protein product while minimizing the toxic effects thereof on the host.
Owner:RENESSELAER POLYTECHNIC INST

Methods for improving genome engineering and regeneration in plants II

ActiveCN112585269BImprove stable conversion efficiencyImprove production efficiencyPlant peptidesFermentationBiotechnologyVersus gene
This document relates to methods and materials for genome engineering in eukaryotic cells, and in particular to methods for increasing the efficiency of genome engineering (i.e., transformation or genome editing) by co-delivering a combination of one or more enhancer polypeptides and enhancer genes with genome engineering components.
Owner:KWS SAAT SE & CO KGAA

Gene editing using homology-independent universal genome engineering technology

Disclosed herein are the genetic constructs for a Homology-Independent Universal Genome Editing (HiUGE) system and methods of using said HiUGE system for genome editing. The invention relates to compositions comprising gRNA polynucleotides, insert polynucleotides, and a CRISPR-based nuclease or polynucleotide encoding a CRISPR-based nuclease.
Owner:DUKE UNIV

A CRISPR-Cas9 plasmid and its construction method and application

The present invention relates to a CRISPR-Cas9 plasmid and its construction method and application. The nucleotide sequence of the CRISPR-Cas9 plasmid is shown in SEQ ID No. 6. A CRISPR-Cas9 plasmid for Bifidobacterium was constructed using CRISPR-Cas9 technology. By transforming Bifidobacterium with this plasmid, a gene knockout strain can be obtained, which is conducive to more convenient and efficient application in Bifidobacterium genome engineering.
Owner:UNIV OF SHANGHAI FOR SCI & TECH

Construction method and application of animal model for research on HPV pathogenic mechanism

The invention discloses a construction method and application of an animal model for HPV (human papillomavirus) pathogenic mechanism research, and belongs to the technical field of animal models. According to the construction method of the HPV fixed-point integration animal model, HPV16 gene knock-in is carried out on the Col1a1 gene locus of a C57BL / 6J mouse through CRISPR / Cas mediated genome engineering. The method comprises the following steps: (1) designing specific gRNA; (2) constructing a knock-in vector Donor vector; and (3) uniformly mixing Cas9 protein, gRNA and a targeting vector Donor vector to obtain an injection compound, performing micro-injection on the injection compound into a mouse fertilized egg, and sending the injection compound back to a pregnant mouse fallopian tube to cultivate offspring so as to generate a gene knock-in mouse. The animal model prepared by the method can be used as a contrast of a cervical cancer precancerous lesion animal model for scientific research.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Methods and compositions for improving precision of endonuclease-mediated genome editing

Disclosed are methods and compositions for reducing concatemer formation and formation of other artifacts during insertion of donor nucleic acid into a genome. Applications to genome editing and genome-engineered call therapy are also disclosed.
Owner:CARIBOU BIOSCIENCES INC

Particle for the encapsidation of a genome engineering system

ActiveCA3024376CVirus peptidesInactivation/attenuationGag PolyproteinProtide
The invention relates to a retroviral particle comprising a Gag polyprotein-derived protein, an envelope protein, op- tionally an integrase and at least two encapsidated non-viral RNAs, each of said encapsidated non-viral RNAs containing an RNA sequence of interest linked to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain that is introduced into the Gag polyprotein-derived protein and / or into the integrase; furthermore, at least one of the sequences of interest of the encapsidated non-viral RNAs comprises a portion coding for a nuclease.
Owner:FLASH THERAPEUTICS

Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC

Methods for enhancing genome engineering efficiency

This document relates to methods and materials for genome engineering in eukaryotic cells, and particularly to methods for increasing genome engineering (i.e. transformation or genome editing) efficiency via delivery of one or more RKD2 and RKD4 genes, with genome engineering components.
Owner:UNIVERSITY OF WARWICK

High fidelity nucleotide polymerase chimeric prime editor systems

PendingUS20260185068A1NucleotideGenomic engineering
The present invention relates to the field of genomic engineering. In particular, a chimeric prime editing (cPE) system is disclosed comprising elements including, but not limited to a Cas9 nickase (nCas9) / high fidelity nucleotide polymerase (HFNTPol) RNA, one or more single guide RNAs (sgRNAs), and a chimeric prime editor template oligonucleotide (cpetODN) comprising a deoxyribonucleic acid nucleotide polymerase template (NPT) and a primer binding site. For example, the sgRNA and the cpetODN are ligated into a single oligonucleotide. Alternatively, the sgRNA and the cpetODN are free and independent molecules (e.g., modular). This cPE system results in precise and efficient genome editing in cells and in adult mouse liver which is advantageous over conventional sgRNA prime editor fusion constructs. This flexible and modular system is an improvement in the art to obtain precise genome editing.
Owner:UNIV OF MASSACHUSETTS

Vector comprising gene associated with DNA repair deficiency and uses thereof

PCT designated stageWO2026035864A1Nervous disorderHydrolasesProgenitor cellEx vivo
The present disclosure relates, in general, to expression vectors comprising genes associated with DNA repair deficiencies, such as Fanconi anemia (FA), for use in gene therapy to treat DNA repair deficiency disorders. The expression vectors can be introduced directly into the patients or used ex vivo in a method for genome engineering a hematopoietic stem and progenitor cell (HSPC) to express a gene of interest and reintroduced into a patient.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA

Engineering AAV

The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.
Owner:SANGAMO THERAPEUTICS INC

Enhanced immune effector cells and use thereof

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC

Engineered CRISPR-Cas9 nucleases

The present invention relates to engineered CRISPR-Cas9 nucleases. Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genome engineering, epigenome engineering, genome targeting, and genome editing are disclosed.
Owner:THE GENERAL HOSPITAL CORP

PEPTIDE CONJUGATES AND THEIR USE TO PROMOTE IMMUNOTOLERANCY TO CAS NUCLEASES IN GENOME ENGINEERING GENE THERAPY

PEPTIDE CONJUGATES AND THEIR USE FOR PROMOTING IMMUNOTOLERANCY TO CAS NUCLEASES IN GENOME ENGINEERING GENE THERAPY The present invention relates generally to the field of medicine. More particularly, it relates to polypeptide conjugates, compositions, and methods for promoting immunotolerance to the CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein) system, for gene therapy by genome engineering. (No figure)
Owner:ASFALIA BIOLOGICS

Cells with solid tumor targeting backbone and uses thereof

The present invention provides methods and compositions for obtaining functionally enhanced derived effector cells obtained by directed differentiation of genome engineered iPSCs. Also provided are stable and functional genome-edited derived cells that deliver improved or enhanced therapeutic effects. Further provided are therapeutic compositions and uses thereof, the therapeutic compositions comprising the functionally enhanced derived effector cells alone, or comprising the functionally enhanced derived effector cells in combination therapy with an antibody or checkpoint inhibitor.
Owner:FATE THERAPEUTICS INC

Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors

Provided are methods and compositions including for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC

Methods for enhancing genomic engineering efficiency

PendingCN119265223AConvenient inductionHigh induction ratePlant peptidesFermentationProtein deacetylaseGenome engineering
The present document relates to methods and materials for genome engineering in eukaryotic cells, and in particular to methods of increasing the efficiency of genome engineering (i.e. Transformation or genome editing) by co-delivering one or more chemicals such as a protein deacetylase inhibitor, a plant hormone and / or a regeneration enhancing gene with a genome engineering component.
Owner:KWS SAAT SE & CO KGAA

Compositions of and methods for in vitro viral genome engineering

The present disclosure relates to a method of in vitro engineering of nucleic acids. This disclosure further relates to in vitro engineering of viral genomes and to the improvement of viral properties by in vitro genomic engineering of viral genomes. Specifically, the disclosure relates to in vitro viral genomic digestion using RNA-guided Cas9, the assembly of a recombinant genome by the insertion of a DNA or RNA fragment into the digested viral genome and transformation of a host cell with the recombinant genome. This method also related to in vitro engineering for error correction of nucleic acids.
Owner:C3J THERAPEUTICS INC

Cells having solid tumor targeting backbone and use thereof

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC